overview
China steadfastly continues to work regulations on biosimilars to help make the market easier to breakthrough, and the recent Priority Review legislation is a case in point. As the industry continues to evaluate cost, risk and incentives for Biosimilar development, new developments to promote R&D and adjustments to approval pathways are designed to help manufacturing and commercialization of biosimilars.
IBC’s 10th Biosimilars Asia is one of 5 conferences part of the 5th Biopharma Development and Production Week in China. It will address the business case, approvals, future manufacturing strategies and commercialisation, in a market that is expected to be worth $20 billion globally by 2022.
Key Highlights
- CFDAs priority review policy and impact on biosimilars
- The current clinical trial landscape for new biosimilars, and expected pipelines
- The oncology Biosimilars market
- Future manufacturing strategies
- Proving similarity
- Managing product variations
- Innovation and technology breakthroughs for biosimilar development
- Pricing and Promotion strategies
- Commercialisation strategies for the China biosimilars market
- Anticipating investment across the value chain for successful biosimilar commercialisation
For more information, visit www.biopharmaproduction.com >>
agenda
pricing
CNY Pricing
- 2 Day Conference: CNY 6,500
- Group of 2 or more delegates: CNY 5,000
- Group of 4 or more delegates: CNY 4,500
- Pre Conference Workshop: CNY 1,000
- Gala Dinner: CNY 350
Sponsorship
Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.
Partners
speakers
Judith Li
Partner, Lilly Asia Ventures, Hong Kong
Feng Tao
Founding Partner, Biotrack Capital, China
He Ting
Chief Executive Officer, ImmunoChina, China
Dong Wei
CEO, Edigene, China
Peter Luo
CEO, Adagene Pharma, China
Jonathan Zhao
Co-Founder and Executive Chairman, TRANSCENTA HOLDING, China
Dr Wu Youling
Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China
Dr. Manfred Weiler
Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK
Dr Lin Shiwen
Vice President of Downstream Process Development, WuXi Biologics, China
Dr Zou Linglong
Executive Director, Head of Bioanalytics, Shanghai Henlius Biotech, China
Frank Ye
Senior Vice President, Technical Operations, Hangzhou JUST Biotherapeutics, China
Dr Dennis Lin
Supervisor, Upstream Process Development, Mycenax Biotech Inc, Taiwan
Asif Mahmood
Disease Area Cluster Lead, Pfizer, USA
Dr Peter Pang
General Manager, XiKang (Wuhan) Biopharmaceutical Co.Ltd., EVP, Corporate Head of Regulatory Affairs, JHL Biotech Inc, China
Sumimasa Nagai
Deputy Director of the Translational Research Centre / Clinical Expert Advisor at the Office of New Drug V (Oncology) and Companion Diagnostics Working Group, University of Tokyo Hospital / Pharmaceuticals and Medical Devices Agency, Japan
Dr Jiang Weidong
Vice President and Chief Scientific Officer, Shanghai Henlius Biotech, China
Wang Yongzhong
President of Pharmaceuticals, Executive Vice President, Simcere Pharmaceutical Group, China
Dr Jerry Dong
Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.
Chen-Yuan Lin
Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan
Dr. Jerry Yang
Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China
Xiaodi Su
Senior Investment Manager, Lilly Asia Ventures, China
Jieyu Zou
Vice President, Lilly Asia Ventures, China
